

Karakeçi A.¹, Keles A.², Onur R.³

¹Firat University School of Medicine, Dept. of Urology, Istanbul, Turkey, ²Istanbul Esenyurt State Hospital, Dept. of Urology, Istanbul, Turkey,

³Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey

Introduction & Objectives: To investigate efficacy and safety of botulinum toxin in patients who applied to our clinic with overactive bladder (OAB) symptoms associated with idiopathic detrusor overactivity.

Materials & Methods: Data of 40 patients who administered 100 units Botulinum toxin injection by the same surgeon due to OAB between 2015 and 2018 were evaluated retrospectively. Treatment success was assessed by the treatment benefit scale (TBS) which was filled at third month of the injection. Health-related quality of life regarding OAB symptoms were assessed before and 3 months after the treatment by incontinence quality of life scale. In addition, pre-procedural and post-procedural third month incontinence, frequency, nocturia, the number of pads they used, maximum urinary flow rate, and post-micturition residual urine values were recorded.

Results: While the incontinence quality of life (I-QoL) scores were high enough to be directly proportional to the severity of the symptoms before the procedure, significant increases were found in all three groups of the post-treatment questionnaire (38.5 ± 15.0 vs. 69.9 ± 6.3 , respectively; $p < 0.001$), TBS at third month showed that 80% of our patients reported benefit from the treatment.

	Min-Max	Median	Mean.±s.d	p
IQoL				
Pre-op	46.0 – 80.0	70.0	69.9 ± 6.3	<0.001
Post-op	22.0 – 70.0	33.0	38.5 ± 15.0	
Pad Number (n)				
Pre-op	0.0 – 5.0	3.0	2.3 ± 1.9	<0.001
Post-op	0.0 – 5.0	1.0	1.0 ± 1.4	
Frequency (episodes/day)				
Pre-op	3.0 – 20.0	12.0	12.3 ± 4.1	<0.001
Post-op	2.0 – 15.0	5.0	6.7 ± 3.8	
Nocturia (episodes/day)				
Pre-op	2.0 – 5.0	3.0	3.6 ± 1.0	<0.001
Post-op	0.0 – 5.0	1.0	1.6 ± 1.1	
Incontinence (episodes/day)				

Pre-op	0.0- 10.0	3.0	3.5 ± 3.0	
Post-op	0.0 – 7.0	0.0	1.1 ± 1.6	<0.001
PMR (ml)				
Pre-op	0.0 – 40.0	20.0	20.5 ± 11.7	
Post-op	0.0 – 35.0	15.0	17.3 ± 10.5	0.718
Qmax				
Pre-op	13.0 – 38.0	20,0	22.1 ± 6.7	
Post-op	10.0 – 40.0	18.0	20.6 ± 6.9	0.649

Table 1. Change from baseline in daily average episodes and total I-QOL scores.

IQoL: incontinence quality of life

Qmax: maximum urinary flow rate

PMR: post-micturition residual urine

Conclusions: Botulinum toxin injection is a safe treatment option with high success and low side effect rate in the treatment of overactive bladder.